Similarly, IL-2 contributes to a favorable response to ICI therapy by regulating leukocyte activity, interacting with antibodies, promoting hematopoiesis and tumor surveillance, and inducing NK cells to produce cytokines such as IFN-γ and tumor necrosis factor-α (TNF-α) [196,198]. The gene discussed is TNF; the disease is neoplasm.